The most common molecular subtype of breast cancer, ER + /HER2−, poses challenges in determining the need for adjuvant chemotherapy as it can recur up to 20 years or more after initial diagnosis1–4,6,7. The gene discussed is ESR1; the disease is breast carcinoma.